Resources Repository
-
ArticlePublication 2015Universal Public Finance of Tuberculosis Treatment in India: An Extended CEA
This paper evaluates the consequences of universal public finance (UPF) for tuberculosis treatment in India …
This paper evaluates the consequences of universal public finance (UPF) for tuberculosis treatment in India using extended cost-effectiveness analysis (ECEA). The authors evaluated the impact of UPF on health gains, financial consequences, and catastrophic health expenditures, and concluded that the health gains and insurance value of UPF would accrue mostly to the poor. However, reductions in out-of-pocket expenditures were found to be more uniformly distributed across income quintiles. A variant on the base case suggests…
Priority Setting/Ethics | Cost-Effectiveness Analysis | Health/Medicine | Asia & Pacific | Health Systems | Costing Methods | Health Outcomes | Infectious Diseases | Social Determinants | Policy/Regulation | Clinical Care | Economics/Finance -
ArticlePublication 2015Benefits of Scaling a Home-Based Neonatal Care Package in Rural India
In 2011, India introduced a home-based newborn care (HBNC) package to be delivered by community …
In 2011, India introduced a home-based newborn care (HBNC) package to be delivered by community health workers across rural areas. The authors estimate the disease and economic burden that could be averted by scaling up the HBNC in rural India using IndiaSim, an agent-based simulation model. Under one scenario, the existing community health worker network begins providing HBNC for rural households without access to home- or facility-based newborn care. In the second scenario, coverage of…
Microsimulation | Cost-Effectiveness Analysis | Health/Medicine | Asia & Pacific | Health Systems | Costing Methods | Child/Nutrition | Culture/Society -
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
Priority Setting/Ethics | Cost-Effectiveness Analysis | Health/Medicine | North America | Health Systems | Technology Assessment | Infectious Diseases | Child/Nutrition | Chronic Disease/Risk | Policy/Regulation | Economics/Finance | Government/Law -
ReviewPublication 2014Valuing Vaccination
Vaccination has led to remarkable health gains over the last century. However, large coverage gaps …
Vaccination has led to remarkable health gains over the last century. However, large coverage gaps remain, which will require significant financial resources and political will to address. In recent years, a compelling line of inquiry has established the economic benefits of health, at both the individual and aggregate levels. Most existing economic evaluations of particular health interventions fail to account for this new research, leading to potentially sizable undervaluation of those interventions. In line with…
Priority Setting/Ethics | Preferences/Values | Health/Medicine | Global | Health Systems | Costing Methods | Benefit-Cost Analysis | Infectious Diseases | Economics/Finance -
ArticlePublication 2014Cost-Effectiveness of Female HPV Vaccination in 179 Countries: A PRIME Modelling Study
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), …
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), used to assess cost-effectiveness and health effects of vaccination of girls against HPV before sexual debut in terms of burden of cervical cancer and mortality. The PRIME models incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical cancer incidence and mortality, and HPV type distribution. It assumes lifelong vaccine protection and no changes to other screening programs…
Cost-Effectiveness Analysis | Health/Medicine | Asia & Pacific | Global | Health Systems | Health Outcomes | Mathematical Models | Calibration/Validation | Infectious Diseases | Chronic Disease/Risk | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean -
ReviewPublication 2013Role of Health Economic Analyses in Vaccine Decision Making
Beginning in the 20th century with the consideration of the seven-valent pneumococcal conjugate vaccine in …
Beginning in the 20th century with the consideration of the seven-valent pneumococcal conjugate vaccine in the US, cost effectiveness became a topic of discussion when a vaccine was being considered for universal use by the US Advisory Committee on Immunization practices (ACIP). In 2008, the ACIP began using formal criteria for the presentation of such data and their inclusion in ACIP discussions. More recently, the U.S. Institute of Medicine has recommended that health economic considerations play a…
Priority Setting/Ethics | Cost-Effectiveness Analysis | Health/Medicine | North America | Health Systems | Infectious Diseases | Economics/Finance -
ArticlePublication 2011Model-Based Analyses to Compare Health and Economic Outcomes of Cancer Control: Inclusion of Disparities
In order to identify strategies that improve both population health and ensure its equitable distribution, …
In order to identify strategies that improve both population health and ensure its equitable distribution, the authors developed a typology of cancer disparities that considers types of inequalities among black, white, and Hispanic populations across different cancers. This paper reports on the typology using an existing disease simulation model of cervical cancer that was calibrated to clinical, epidemiological, and cost data in the United States and presents characteristics important for policy discussions. The typology proposed…
Priority Setting/Ethics | Cost-Effectiveness Analysis | Health/Medicine | North America | Health Systems | State-Transition | Chronic Disease/Risk | Social Determinants | Clinical Care | Culture/Society | Science/Technology -
ArticlePublication 2008Health and Economic Implications of HPV Vaccination in the U.S.
This article reports on a study using models of HPV-16 and HPV-18 transmission and cervical …
This article reports on a study using models of HPV-16 and HPV-18 transmission and cervical carcinogenesis to compare the health and economic outcomes of vaccinating preadolescent girls in the US (at 12 years of age), and vaccinating older girls and women in catch-up programs (to 18, 21, or 26 years of age). The study also examined the health benefits of averting other HPV-16-related and HPV-18-related cancers, the prevention of HPV-6-related and HPV-11-related genital warts and…
Microsimulation | Cost-Effectiveness Analysis | Health/Medicine | North America | Health Systems | Dynamic Transmission | Calibration/Validation | Infectious Diseases | Chronic Disease/Risk | Clinical Care | Economics/Finance | Science/Technology -
ArticlePublication 2008Mathematical Models of Cervical Cancer Prevention in the Asia Pacific Region
This article reports on a model-based approach to estimate averted cervical cancer cases and deaths, …
This article reports on a model-based approach to estimate averted cervical cancer cases and deaths, disability-adjusted life years (DALYs) and incremental cost-effectiveness ratios (I$/DALY averted) for vaccination of young adolescent girls against human papillomavirus (HPV) types 16 and 18. The authors used population-based and epidemiologic data for 25 countries in Asia (22 GAVI-Alliance eligible countries, Thailand, China and Japan). They found that an absolute reduction in lifetime cancer risk varied across countries, depending on incidence,…
Microsimulation | Cost-Effectiveness Analysis | Health/Medicine | Asia & Pacific | Health Systems | Mathematical Models | Calibration/Validation | Infectious Diseases | Chronic Disease/Risk | Economics/Finance | Science/Technology